DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20170644

Heat shock protein 60 and chromatin assembly factor-1 mRNA levels in hepatitis C virus-related hepatocellular carcinoma and clinical significance

Fatma M. Abd El-Salam, Entesar H. El-Sharqawy, Hala M. El-feky, Shuzan A. Mohammed, Ahmed M. Edres

Abstract


Background: Hepatocellular carcinoma (HCC) is the third cause of cancer-related death worldwide. Heat Shock protein 60 (HSP60), a mitochondrial chaperone, is overexpressed in diverse malignant cells. Chromatin Assembly Factor-1 (CAF-1), a histone chaperone, is down-regulated in quiescent non-proliferating human cells. We aimed to clarify the role of HSP60 and CAF-1 mRNA expression in diagnosis of HCC post-HCV infection.

Methods: HSP60 and CAF-1 mRNA levels in urine and blood were quantified by Taqman real-time PCR in 49 subjects; 25 cirrhotic with HCV-related HCC, 12 cirrhotic without HCC and 12 healthy controls.

Results: HSP60 and CAF-1 mRNA levels in urine and blood were significantly higher in HCC versus cirrhosis and controls, and in cirrhosis versus controls. Their levels in HCC were significantly increased by advancement of HCC BCLC staging system. HSP60 in urine had 85% sensitivity and 66% specificity at cut off 258354 RU and 85% sensitivity and 60 % specificity at cut off 37576 RU in blood for HCC diagnosis. CAF-1 in urine had 81% sensitivity and 66% specificity at cut off 137756 RU and 77% sensitivity and 64% specificity at cut off 49726 RU in blood for HCC diagnosis. HSP60/CAF-1 sensitivity and specificity in urine and blood were better than either marker alone, with better results in urine (91% and 73%, respectively) than blood (88% and 66%, respectively).

Conclusions: HSP60 and CAF-1 in urine and blood may be useful HCC diagnostic markers that were correlated with advancement of HCC with better combined marker sensitivity and specificity than either marker alone especially for urine.


Keywords


CAF-1, Gene expression, HCC, HSP60, Taqman real-time PCR, Urine

Full Text:

PDF

References


Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.

Bosch FX, Ribes J, Cleries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.

Fukuda S, Itamoto T, Nakahara H, Hino H, Toshihiko A, Kohashi M. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepato-gastroenterology. 2005;52:1163-7.

Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1:593-8.

Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. Circulation. 2002;105:1012-7.

Calderwood SK, Xie Y, Wang X, Khaleque MA, Chou SD, Murshid A, et al. Signal transduction pathways leading to heat shock transcription. Sign Transduct Insights. 2010;2:13-24.

Seigneuric R, Mjahed H, Gobbo J, Joly AL, Berthenet K, Shirley S, et al. Heat shock proteins as danger signals for cancer detection. Front Oncol. 2011;1:37.

Zhang J, Zhou X, Chang H, Huang X, Guo X, Du X, et al. HSP60 exerts a tumor suppressor function by inducing cell differentiation and inhibiting invasion in hepatocellular carcinoma. Oncotarget 2016;7:68976-89.

Polo SE, Theocharis SE, Klijanienko J, Savignoni A, Asselain B, Vielh P, et al. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res. 2004;64:2371-81.

Mello JA, Almouzni G. The ins and outs of nucleosome assembly. Curr Opin Genet Dev. 2001;11:136-41.

Abdalla MA, Haj-Ahmad Y. Promising urinary protein biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis c virus Egyptian patients. J. Cancer. 2012;3:390-403.

Polo SE, Theocharis SE, Grandin L, Gambotti L, Antoni G, Savignoni A, et al. Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours. Histopathology. 2010;57:716-24.

O'Driscoll L. Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. Anticancer Res. 2007;27:1257-65.

Goessl C. Noninvasive molecular detection of cancer: the bench and the bedside. Curr Med Chem. 2003;10:691-706.

Buttarello M, Plebani M. Automated blood cell counts: state of the art. American journal of clinical pathology. 2008;130:104-16.

Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest. 1992;102(4 Supplement):312S-26S.

Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American J Clin Pathol. 1957;28:56-63.

Teitz NW, Shuey DF. Kinetic determination of alkaline phosphatase activity. Clin Chem. 1986;32:1593.

Dumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87-96.

Malloy HT, Evelyn K The determination of bilirubin with the photoelectric colorimeter. Biol Chem J. 1937;119:481-90.

Henry RJ. Determination of creatinine by kinetic method. In: clinical chemistry, principles and technics, 2nd edition, Harper & Rowe. 1974:525.

Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996;77:2217-22.

Blumberg BS, Sutnick AI, London WT, Millman J. The discovery of Australian antigen and its relation to viral hepatitis. Perspect Virology. 1971;7:223-40.

Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993;67:1385-95.

Dominguez K, Ward WS. A novel nuclease activity that is activated by Ca2+ chelated to EGTA. Systems Biology in Reproductive Medicine. 2009;55:193-99.

Wilfinger WW, Mackey K, Chomczynski P. Effect of pH and ionic strength on the spectrophotometric assessment of nucleic acid purity. Biotechniques. 1997;22:474-81.

Livak K, Schmittgen, T. Analysis of relative gene expression data using real-time quantitative PCR and the 2∆∆CT method. Methods. 2001;25:402-8.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.

Omar A, Abou-Alfa GK, Khairy A, Omar H. Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol. 2013;2:43.

Abdel-Atti E. HCC Burden in Egypt. Gastroenterology & Hepatology J. 2015;2(3):00045.

Hass HG, Vogel U, Scheurlen M, Jobst J. Gene-expression analysis identifies specific patterns of dysregulated molecular pathways and genetic subgroups of human hepatocellular carcinoma. Anticancer Res. 2016;36:5087-95.

Abdelaziz AO, Elbaz TM, Shousha HI, Ibrahim MM, Rahman El-Shazli MA et al. Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev. 2014;15:3915-20.

Keng VW, Sia, D, Sarver AL, Tschida BR, Fan D, Alsinet C et al. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology. 2013;57:120-30.

Beere HM. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis". J. Cell Sci. 2004;117:2641-51.

Kuramitsu Y, Nakamura K. Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteomics. 2005;2:589-601.

Lin CY, Hu CT, Cheng CC, Lee MC, Pan SM, Lin TY, et al. Oxidation of heat shock protein 60 and protein disulfide isomerase activates ERK and migration of human hepatocellular carcinoma HepG2. Oncotarget. 2016;7:11067-82.

Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol. 2005;11:2072-9.

Li X, Ding M, Sun R, Wang Q, Qu C, Meng R, et al. Analysis of the expression of chromatin assembly factor 1 subunit A in multiple tumors and its clinical significance by utilizing GEO datasets. Tumor. 2014;34:642-50.

Xu M, Jia Y, Liu Z, Ding L, Tian R, Gu H, et al. Chromatin assembly factor 1, subunit A(P150) facilitates cell proliferation in human hepatocellular-carcinoma. Onco Targets Ther. 2016;9:4023-35.

Joo M, Chi J, Lee H. Expressions of HSP70 and HSP27 in Hepatocellular Carcinoma. J Korean med. sci. 2005;20:829-34.

Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, Dionigi G, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015;360:114-8.

Bryzgunova OE, Laktionov PP. Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential Acta Naturae. 2015;7:48-54.

Hanke M, Kausch I, Dahmen G, Jocham D, Warnecke JM. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem. 2007;53:2070-7.